Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
Rank in Stocks
#3618
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical... Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is a biopharmaceutical firm that handles the entire process from research and development to the production, marketing, and distribution of diagnostic solutions for infectious diseases and various vaccines. The company operates extensively across China and in international markets. Its comprehensive product range offers diagnostic test kits for a multitude of infectious agents, including COVID-19, HIV, HTLV, Hepatitis, EV-71, and Tuberculosis. It also provides specific detection reagents for Hepatitis C and Syphilis. Beyond these, the portfolio includes advanced diagnostic tools such as automated immunoassays, ELISA kits, rapid diagnostic tests, and various chemiluminescence, clinical chemistry, and general immunodiagnostic reagents. Furthermore, Beijing Wantai is a developer and supplier of vaccines for Hepatitis E and human papillomavirus (HPV). The company serves a wide array of clients, including blood banks, hospitals and clinics, specialized reference laboratories, border inspection centers, blood-processing companies, and scientific research institutes. Established in 1991, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. is headquartered in China's capital city, Beijing.
Share Price
$3.71
Market Cap
$4.69B
Change (1 day)
2.44%
Change (1 year)
-51.92%
Country
CN
Trade Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
Category
Healthcare
P/B ratio for Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392)
P/B ratio as of October 2026 TTM: 2.70
According to Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 2.70. At the end of 2023 the company had a P/B ratio of 7.46.
P/B ratio history for Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. from 2013 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 2.70 | -64.57% |
| 2024 | 7.63 | 2.35% |
| 2023 | 7.46 | -18.64% |
| 2022 | 9.16 | -63.42% |
| 2021 | 25.05 | -9.41% |
| 2020 | 27.65 | 962.67% |
| 2019 | 2.60 | -10.83% |
| 2018 | 2.92 | -31.74% |
| 2017 | 4.28 | 0.30% |
| 2016 | 4.26 | -22.48% |
| 2015 | 5.50 | -15.25% |
| 2014 | 6.49 | -31.92% |
| 2013 | 9.53 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | 131.26% |
US
|
|
| 13.2547 | 390.37% |
US
|
|
| 4.208 | 55.68% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 128.72% |
NL
|
